^
Association details:
| Biomarker: | EGFR mutation + LINC00460 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib
Published date:
07/20/2023
Excerpt:
The present study investigated the clinical significance of LINC00460 expression in patients with epidermal growth factor receptor (EGFR) mutation‑positive lung cancer treated with osimertinib....following osimertinib therapy, PFS was significantly shorter for patients with high LINC00460 expression in plasma cell‑free RNA (n=12) than for those with low LINC00460 expression (n=12) (median PFS: 655 days vs. 210 days; P=0.020).
DOI:
https://doi.org/10.3892/ol.2023.13966
